ArticleIET nanobiotechnology2020
Iron oxide/gold nanoparticles-decorated reduced graphene oxide nanohybrid as the thermo-radiotherapy agent.
Article in IET nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Green-synthesized MnFe₂O₄/GO nanocomposites: structural characterization, cytotoxicity, and potential for targeted cervical cancer therapy.Cancer cell international · 2025Article
- The Refined Application and Evolution of Nanotechnology in Enhancing Radiosensitivity During Radiotherapy: Transitioning from Gold Nanoparticles to Multifunctional Nanomaterials.International journal of nanomedicine · 2023Review
- Advances of Nanomedicine in Radiotherapy.Pharmaceutics · 2021Review
- Numerical Investigation of Ferrofluid Preparation during In-Vitro Culture of Cancer Therapy for Magnetic Nanoparticle Hyperthermia.Sensors (Basel, Switzerland) · 2021Article
- Synthesis, radiolabelling, and biological assessment of folic acid-conjugated G-3IET nanobiotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main focus of the current study is the fabrication of a multifunctional nanohybrid based on graphene oxide (GO)/iron oxide/gold nanoparticles (NPs) as the combinatorial cancer treatment agent. Gold and iron oxide NPs formed on the GONPs via the in situ synthesis approach. The characterisations showed that gold and iron oxide NPs formed onto the GO. Cell toxicity assessment revealed that the fabricated nanohybrid exhibited negligible toxicity against MCF-7 cells in low doses (<50 ppm). Temperature measurement showed a time and dose-dependent heat elevation under the interaction of the nanohybrid with the radio frequency (RF) wave. The highest temperature was recorded using 200 ppm concentration nanohybrid during 40 min exposure. The combinatorial treatments demonstrated that the maximum cell death (average of 53%) was induced with the combination of the nanohybrid with RF waves and radiotherapy (RT). The mechanistic study using the flow cytometry technique illustrated that early apoptosis was the main underlying cell death. Moreover, the dose enhancement factor of 1.63 and 2.63 were obtained from RT and RF, respectively. To sum up, the authors' findings indicated that the prepared nanohybrid could be considered as multifunctional and combinatorial cancer therapy agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.